NCT05635162 - Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Zanubrutinib

Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.

DRUG

Rituximab

Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle

Trial Locations (13)

RECRUITING

Royal Derby Hospital, Derby

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

RECRUITING

Clatterbridge Cancer Centre, Liverpool

RECRUITING

Guy's Hospital, London

RECRUITING

St Bartholomew's Hospital, London

RECRUITING

University College London Hospital, London

RECRUITING

Christie Hospital, Manchester

RECRUITING

Norfolk and Norwich University Hospitl, Norwich

RECRUITING

Nottingham City Hospital, Nottingham

RECRUITING

Churchill Hospital, Oxford

RECRUITING

Derriford Hospital, Plymouth

RECRUITING

Southampton General Hospital, Southampton

RECRUITING

Royal Cornwall Hospital, Truro